215 related articles for article (PubMed ID: 22272243)
1. Anti-tumor effect against human cancer xenografts by a fully human monoclonal antibody to a variant 8-epitope of CD44R1 expressed on cancer stem cells.
Masuko K; Okazaki S; Satoh M; Tanaka G; Ikeda T; Torii R; Ueda E; Nakano T; Danbayashi M; Tsuruoka T; Ohno Y; Yagi H; Yabe N; Yoshida H; Tahara T; Kataoka S; Oshino T; Shindo T; Niwa S; Ishimoto T; Baba H; Hashimoto Y; Saya H; Masuko T
PLoS One; 2012; 7(1):e29728. PubMed ID: 22272243
[TBL] [Abstract][Full Text] [Related]
2. Antibody against CD44s inhibits pancreatic tumor initiation and postradiation recurrence in mice.
Li L; Hao X; Qin J; Tang W; He F; Smith A; Zhang M; Simeone DM; Qiao XT; Chen ZN; Lawrence TS; Xu L
Gastroenterology; 2014 Apr; 146(4):1108-18. PubMed ID: 24397969
[TBL] [Abstract][Full Text] [Related]
3. Adhesive interactions between alternatively spliced CD44 isoforms.
Droll A; Dougherty ST; Chiu RK; Dirks JF; McBride WH; Cooper DL; Dougherty GJ
J Biol Chem; 1995 May; 270(19):11567-73. PubMed ID: 7538117
[TBL] [Abstract][Full Text] [Related]
4. ChLpMab-23: Cancer-Specific Human-Mouse Chimeric Anti-Podoplanin Antibody Exhibits Antitumor Activity via Antibody-Dependent Cellular Cytotoxicity.
Kaneko MK; Nakamura T; Kunita A; Fukayama M; Abe S; Nishioka Y; Yamada S; Yanaka M; Saidoh N; Yoshida K; Fujii Y; Ogasawara S; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Jun; 36(3):104-112. PubMed ID: 28504613
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of tumor formation and metastasis by a monoclonal antibody against lymphatic vessel endothelial hyaluronan receptor 1.
Hara Y; Torii R; Ueda S; Kurimoto E; Ueda E; Okura H; Tatano Y; Yagi H; Ohno Y; Tanaka T; Masuko K; Masuko T
Cancer Sci; 2018 Oct; 109(10):3171-3182. PubMed ID: 30058195
[TBL] [Abstract][Full Text] [Related]
6. Radiotheranostic Targeting Cancer Stem Cells in Human Colorectal Cancer Xenografts.
She X; Qin S; Jing B; Jin X; Sun X; Lan X; An R
Mol Imaging Biol; 2020 Aug; 22(4):1043-1053. PubMed ID: 32125599
[TBL] [Abstract][Full Text] [Related]
7. CD44v10, osteopontin and lymphoma growth retardation by a CD44v10-specific antibody.
Megaptche AP; Erb U; Büchler MW; Zöller M
Immunol Cell Biol; 2014 Sep; 92(8):709-20. PubMed ID: 24935458
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor activity of a novel monoclonal antibody, NPC-1C, optimized for recognition of tumor antigen MUC5AC variant in preclinical models.
Patel SP; Bristol A; Saric O; Wang XP; Dubeykovskiy A; Arlen PM; Morse MA
Cancer Immunol Immunother; 2013 Jun; 62(6):1011-9. PubMed ID: 23591984
[TBL] [Abstract][Full Text] [Related]
9. Ligand binding specificity of alternatively spliced CD44 isoforms. Recognition and binding of hyaluronan by CD44R1.
Dougherty GJ; Cooper DL; Memory JF; Chiu RK
J Biol Chem; 1994 Mar; 269(12):9074-8. PubMed ID: 7510702
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of a monoclonal antibody targeting major histocompatibility complex class I-Her2 peptide complexes.
Jain R; Rawat A; Verma B; Markiewski MM; Weidanz JA
J Natl Cancer Inst; 2013 Feb; 105(3):202-18. PubMed ID: 23300219
[TBL] [Abstract][Full Text] [Related]
11. A novel anti-EGFR monoclonal antibody inhibiting tumor cell growth by recognizing different epitopes from cetuximab.
Hong KW; Kim CG; Lee SH; Chang KH; Shin YW; Ryoo KH; Kim SH; Kim YS
J Biotechnol; 2010 Jan; 145(1):84-91. PubMed ID: 19828124
[TBL] [Abstract][Full Text] [Related]
12. A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo.
Brezski RJ; Kinder M; Grugan KD; Soring KL; Carton J; Greenplate AR; Petley T; Capaldi D; Brosnan K; Emmell E; Watson S; Jordan RE
MAbs; 2014; 6(5):1265-73. PubMed ID: 25517311
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a high-affinity monoclonal antibody specific for CD44v6 as candidate for immunotherapy of squamous cell carcinomas.
Heider KH; Sproll M; Susani S; Patzelt E; Beaumier P; Ostermann E; Ahorn H; Adolf GR
Cancer Immunol Immunother; 1996 Dec; 43(4):245-53. PubMed ID: 9003471
[TBL] [Abstract][Full Text] [Related]
14. CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients.
Birzele F; Voss E; Nopora A; Honold K; Heil F; Lohmann S; Verheul H; Le Tourneau C; Delord JP; van Herpen C; Mahalingam D; Coveler AL; Meresse V; Weigand S; Runza V; Cannarile M
Clin Cancer Res; 2015 Jun; 21(12):2753-62. PubMed ID: 25762343
[TBL] [Abstract][Full Text] [Related]
15. CD44 staining of cancer stem-like cells is influenced by down-regulation of CD44 variant isoforms and up-regulation of the standard CD44 isoform in the population of cells that have undergone epithelial-to-mesenchymal transition.
Biddle A; Gammon L; Fazil B; Mackenzie IC
PLoS One; 2013; 8(2):e57314. PubMed ID: 23437366
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen.
Huang X; Bennett M; Thorpe PE
Prostate; 2004 Sep; 61(1):1-11. PubMed ID: 15287089
[TBL] [Abstract][Full Text] [Related]
17. CD44 and the adhesion of neoplastic cells.
Rudzki Z; Jothy S
Mol Pathol; 1997 Apr; 50(2):57-71. PubMed ID: 9231152
[TBL] [Abstract][Full Text] [Related]
18. A defucosylated anti‑CD44 monoclonal antibody 5‑mG2a‑f exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma.
Takei J; Kaneko MK; Ohishi T; Hosono H; Nakamura T; Yanaka M; Sano M; Asano T; Sayama Y; Kawada M; Harada H; Kato Y
Oncol Rep; 2020 Nov; 44(5):1949-1960. PubMed ID: 33000243
[TBL] [Abstract][Full Text] [Related]
19. Nectin-2 is a potential target for antibody therapy of breast and ovarian cancers.
Oshima T; Sato S; Kato J; Ito Y; Watanabe T; Tsuji I; Hori A; Kurokawa T; Kokubo T
Mol Cancer; 2013 Jun; 12():60. PubMed ID: 23758976
[TBL] [Abstract][Full Text] [Related]
20. Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody.
Huang S; Li F; Liu H; Ye P; Fan X; Yuan X; Wu Z; Chen J; Jin C; Shen B; Feng J; Zhang B
MAbs; 2018; 10(6):864-875. PubMed ID: 30081724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
